News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Mandy Davis Aitken Shares ASCO25 Travel Tip: Free Digital Metra Tickets Return
Mandy Davis Aitken/cmss.org
May 28, 2025, 07:14

Mandy Davis Aitken Shares ASCO25 Travel Tip: Free Digital Metra Tickets Return

Mandy Davis Aitken, Vice President of ASCO Meeting Services, posted on X:

“ASCO25 pro tip— Free Metra tickets from McCormick to Millenium Park are back for 2025 and this year they are digital.
Stop by the Metra desk on level 2.5 with any questions.”

Read Further.

Further Reading: ASCO 2025.

ASCO25 cancer Mandy Davis Aitken OncoDaily Oncology
Special Coverage
Science
Sep 5, 2025, 13:14
Myeloma Paper of the Day, September 5th, Suggested by Robert Orlowski
Voices
Sep 5, 2025, 12:59
Fabio Ynoe de Moraes: Two Very Different Stories are Emerging About AI in Research
Insight
Sep 5, 2025, 12:58
Gianluca Franceschini: Inside the Integrated Breast Center of Gemelli Polyclinic
Voices
Sep 5, 2025, 12:51
How a Clinical Trial Gave Molly a Second Chance at Life - Conquer Cancer, the ASCO Foundation
Insight
Sep 5, 2025, 12:31
Courtney Jones: A New Publication From the Lab in Blood
Voices
Sep 5, 2025, 12:12
Jennifer Sullivan: Bringing "The Best of What We Are Wherever You Are"
Voices
Sep 5, 2025, 12:06
Armando Orlandi: Extraordinary Success for the 17th Breast Club!
Voices
Sep 5, 2025, 11:58
Roupen Odabashian: How WorkDone Health Tackles a $125B Healthcare Problem
Insight
Sep 5, 2025, 11:56
Eric Small on FY26 Budget: Saving Research Means Saving Lives
Voices
Sep 5, 2025, 11:45
Annalice Gandini: A Case Report on the Successful Use of Dual EGFR Blockade
Voices
Sep 5, 2025, 11:43
Conquering Underfunded and Rare Cancers Through Research - Conquer Cancer, the ASCO Foundation
Science
Sep 5, 2025, 11:34
Harpreet Singh: FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC